Kaiku Health joins forces with Novartis for melanoma monitoring and support

MobiHealthNews) 
Kaiku Health, maker of an oncology-focused platform that collected patient-reported outcomes, is teaming up with pharma giant Novartis on a new initiative to help monitor and manage melanoma.
The companies will zero in on creating a remote monitoring and support network for patients receiving a specific drug combination, known as BRAF and MEK inhibitors, that aims to treat melanoma. As part of the program, the pair will develop a new tool on Kaiku's platform to track the symptoms of patients taking the medications and provide a management guide and patient-education tools.
Caregivers will get an automatic notification if a patient is reporting worsening symptoms in order to intervene. The new program will roll out in Europe first, starting in Germany, Netherlands, Switzerland and Italy in May 2021.

Related Keywords

Germany , Italy , Sweden , United States , Netherlands , Switzerland , American , Swedish , Enerzair Breezhaler , Novartis Sandoz , Lauri Sippola , Amgen , Kaiku Health , American Cancer Society , Propeller Health , Novartis , ஜெர்மனி , இத்தாலி , ஸ்வீடந் , ஒன்றுபட்டது மாநிலங்களில் , நெதர்லாந்து , சுவிட்சர்லாந்து , அமெரிக்கன் , ஸ்விட்ச் , நோவர்த்திச் சாண்டோஸ் , மகேன் , அமெரிக்கன் புற்றுநோய் சமூகம் , ப்ரொபெலர் ஆரோக்கியம் , நோவர்த்திச் ,